Literature DB >> 2350532

Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects.

T Andersson1, K Andrén, C Cederberg, P O Lagerström, P Lundborg, I Skånberg.   

Abstract

1. Ten healthy subjects were given 20 mg omeprazole EC (enteric coated) granules once daily for 8 days. An i.v. tracer dose of [14C]-omeprazole was given simultaneously with the first and last oral doses and blood sampling was performed thereafter. In order to study the extent of absorption at minimal acid exposure, a single dose of 20 mg omeprazole was also given as a buffered solution, before and after the treatment with EC granules. 2. Kinetic parameters of omeprazole after the i.v. tracer dose were unchanged on repeated dosing while AUC increased by approximately 40% for the solution and 60% for the EC granules. 3. The increased AUC is caused by an increased systemic availability, which may be explained by a decreased first-pass elimination during repeated treatment and/or by a reduced degradation of omeprazole in the stomach secondary to the profound decrease in intragastric acidity caused by the drug. 4. The implication of these findings is that the antisecretory effect of therapeutic doses of omeprazole must be studied during repeated administration and not judged from studies using single doses only.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2350532      PMCID: PMC1380155          DOI: 10.1111/j.1365-2125.1990.tb03679.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  The mechanism of action of omeprazole--a survey of its inhibitory actions in vitro.

Authors:  B Wallmark; P Lorentzon; H Larsson
Journal:  Scand J Gastroenterol Suppl       Date:  1985

2.  Healing and relapse of severe peptic esophagitis after treatment with omeprazole.

Authors:  D J Hetzel; J Dent; W D Reed; F M Narielvala; M Mackinnon; J H McCarthy; B Mitchell; B R Beveridge; B H Laurence; G G Gibson
Journal:  Gastroenterology       Date:  1988-10       Impact factor: 22.682

3.  A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers.

Authors:  K D Bardhan; G Bianchi Porro; K Bose; M Daly; R F Hinchliffe; E Jonsson; M Lazzaroni; J Naesdal; L Rikner; A Walan
Journal:  J Clin Gastroenterol       Date:  1986-08       Impact factor: 3.062

4.  Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase.

Authors:  E Fellenius; T Berglindh; G Sachs; L Olbe; B Elander; S E Sjöstrand; B Wallmark
Journal:  Nature       Date:  1981-03-12       Impact factor: 49.962

5.  Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis.

Authors:  E C Klinkenberg-Knol; J M Jansen; H P Festen; S G Meuwissen; C B Lamers
Journal:  Lancet       Date:  1987-02-14       Impact factor: 79.321

6.  Determination of omeprazole and metabolites in plasma and urine by liquid chromatography.

Authors:  P O Lagerström; B A Persson
Journal:  J Chromatogr       Date:  1984-08-10

7.  Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.

Authors:  T Lind; C Cederberg; G Ekenved; U Haglund; L Olbe
Journal:  Gut       Date:  1983-04       Impact factor: 23.059

8.  Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer.

Authors:  A Walan; J P Bader; M Classen; C B Lamers; D W Piper; K Rutgersson; S Eriksson
Journal:  N Engl J Med       Date:  1989-01-12       Impact factor: 91.245

9.  Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage.

Authors:  P J Prichard; N D Yeomans; G W Mihaly; D B Jones; P J Buckle; R A Smallwood; W J Louis
Journal:  Gastroenterology       Date:  1985-01       Impact factor: 22.682

10.  Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro.

Authors:  R Gugler; J C Jensen
Journal:  Gastroenterology       Date:  1985-12       Impact factor: 22.682

  10 in total
  29 in total

1.  Influence of acid secretory status on absorption of omeprazole from enteric coated granules.

Authors:  T Andersson; R Bergstrand; C Cederberg
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 2.  Pharmacokinetic drug interaction profiles of proton pump inhibitors.

Authors:  Henning Blume; Frank Donath; André Warnke; Barbara S Schug
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects.

Authors:  P A Soons; G van den Berg; M Danhof; P van Brummelen; J B Jansen; C B Lamers; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.

Authors:  Tomohiko Shimatani; Masaki Inoue; Tomoko Kuroiwa; Mutsuko Moriwaki; Jing Xu; Kazuro Ikawa; Norifumi Morikawa; Susumu Tazuma
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

5.  Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.

Authors:  Nicole G Hunfeld; Ron A Mathot; Daan J Touw; Ron H van Schaik; Paul G Mulder; Paul F Franck; Ernst J Kuipers; William P Geus
Journal:  Br J Clin Pharmacol       Date:  2008-01-30       Impact factor: 4.335

6.  Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.

Authors:  R H Hunt; D Armstrong; M Yaghoobi; C James; Y Chen; J Leonard; J M Shin; E Lee; D Tang-Liu; G Sachs
Journal:  Aliment Pharmacol Ther       Date:  2008-04-25       Impact factor: 8.171

Review 7.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

8.  Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19.

Authors:  M Chang; G Tybring; M L Dahl; E Götharson; M Sagar; R Seensalu; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

9.  Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.

Authors:  Masato Saito; Norio Yasui-Furukori; Tsukasa Uno; Takenori Takahata; Kazunobu Sugawara; Akihiro Munakata; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

10.  Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.

Authors:  J Dent; N D Yeomans; M Mackinnon; W Reed; F M Narielvala; D J Hetzel; E Solcia; D J Shearman
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.